Publications by authors named "Joyce S Plested"

Claim this Profile
D
Detection of Anti-SARS-CoV-2 Mucosal Immunoglobulin A in Clinical Saliva Samples After a Dose of Novavax COVID-19 Vaccine.
Mingzhu Zhu, Edmond Massuda, Urvashi Patel, Gordon Chau, Raj Kalkeri, Joyce S Plested

J Med Virol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: A phase 3, randomized, placebo-controlled trial (PREVENT-19).
Germán Áñez, Alice McGarry, Wayne Woo, Karen L Kotloff, Cynthia L Gay, Joyce S Plested

Vaccine· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-spike IgG4 and Fc effector responses: The impact of SARS-CoV-2 vaccine platform-specific priming and immune imprinting.
Raj Kalkeri, Mingzhu Zhu, Shane Cloney-Clark, Anand Parekh, Drew Gorinson, Joyce S Plested

J Infect· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity of adjuvanted recombinant SARS-CoV-2 spike protein vaccine after earlier mRNA vaccine doses.
Jeffrey M Adelglass, Paul Bradley, Miranda R Cai, Gordon Chau, Raj Kalkeri, Joyce S Plested

J Allergy Clin Immunol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study.
Katia Alves, Karen Kotloff, R Scott McClelland, Alex Kouassi, Joyce S Plested

Lancet Infect Dis· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of a monovalent Omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine in previously unvaccinated, SARS-CoV-2 seropositive participants: Primary day-28 analysis of a phase 2/3 open-label study.
Katia Alves, Alex Kouassi, Joyce S Plested, Raj Kalkeri, Katherine Smith

Vaccine· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of Omicron protein vaccines in mRNA-vaccinated adolescents: A phase 3, randomised trial.
Chijioke Bennett, Gordon Chau, Erika Clayton, Laurence Chu, Jacqueline Alvarez, Joyce S Plested

J Infect· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanisms and implications of IgG4 responses to SARS-CoV-2 and other repeatedly administered vaccines.
Anthony M Marchese, Louis Fries, Hadi Beyhaghi, Muruga Vadivale, Mingzhu Zhu, Joyce S Plested

J Infect· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-M adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial.
Vivek Shinde, Anthonet Lombard Koen, Zaheer Hoosain, Moherndran Archary, Qasim Bhorat, Joyce S Plested

Hum Vaccin Immunother· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Modified Novel Validated High-Throughput Hemagglutinin Inhibition Assay Using Recombinant Virus-like Particles and Human Red Blood Cells for the Objective Evaluation of Recombinant Hemagglutinin Nanoparticle Seasonal Influenza Vaccine.
Timothy S Vincent, Mingzhu Zhu, Anand Parekh, Urvashi Patel, Shane Cloney-Clark, Joyce S Plested

Microorganisms· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2 Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical Trial.
Chijioke Bennett, E Joy Rivers, Wayne Woo, Mark Bloch, King Cheung, Joyce S Plested

J Infect Dis· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial.
Chijioke Bennett, Wayne Woo, Mark Bloch, King Cheung, Paul Griffin, Joyce S Plested

Lancet Infect Dis· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of a severe acute respiratory syndrome coronavirus 2 microneutralization assay for evaluation of vaccine immunogenicity.
Stephanie Hamilton, Mingzhu Zhu, Shane Cloney-Clark, Penny Mayes, Jen Fenner, Joyce S Plested

J Virol Methods· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of a Pseudovirus Neutralization Assay for Severe Acute Respiratory Syndrome Coronavirus 2: A High-Throughput Method for the Evaluation of Vaccine Immunogenicity.
Zhaohui Cai, Raj Kalkeri, Mi Wang, Benjamin Haner, Dominic Dent, Joyce S Plested

Microorganisms· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Altered IgG4 antibody response to repeated mRNA versus recombinant protein SARS-CoV-2 vaccines.
Raj Kalkeri, Mingzhu Zhu, Shane Cloney-Clark, Joyce S Plested, Anand Parekh

J Infect· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Pseudovirus-Based Neutralization Assay for SARS-CoV-2 Variants: A Rapid, Cost-Effective, BSL-2-Based High-Throughput Assay Useful for Vaccine Immunogenicity Evaluation.
Zhaohui Cai, Raj Kalkeri, Mingzhu Zhu, Shane Cloney-Clark, Benjamin Haner, Joyce S Plested

Microorganisms· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Altered IgG4 Antibody Response to Repeated mRNA versus Protein COVID Vaccines.
Raj Kalkeri, Mingzhu Zhu, Shane Cloney-Clark, Joyce S Plested, Anand Parekh

medRxiv· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults.
Prasad S Kulkarni, Bhagwat Gunale, Sunil Kohli, Sanjay Lalwani, Srikanth Tripathy, Joyce S Plested

Sci Rep· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Strong CD4+ T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 Severe Acute Respiratory Syndrome Coronavirus 2 Primary Vaccination.
Louis Fries, Neil Formica, Raburn M Mallory, Haixia Zhou, Joyce S Plested

J Infect Dis· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Immunoglobulin G Assay: A Robust Method for Evaluation of Vaccine Immunogenicity Using an Established Correlate of Protection.
Mingzhu Zhu, Shane Cloney-Clark, Sheau-Line Feng, Anand Parekh, Drew Gorinson, Joyce S Plested

Microorganisms· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Immunogenicity of SARS-CoV-2 Recombinant Spike Protein Vaccine in Children and Adolescents in India: A Phase 2-3 Randomized Clinical Trial.
Bhagwat Gunale, Dhananjay Kapse, Sonali Kar, Ashish Bavdekar, Sunil Kohli, Joyce S Plested

JAMA Pediatr· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373.
Katia Alves, Joyce S Plested, Shirley Galbiati, Gordon Chau, Shane Cloney-Clark

Vaccine· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity of NVX-CoV2373 in PREVENT-19: A Phase 3, Randomized, Placebo-Controlled Trial in Adults in the United States and Mexico.
Germán Áñez, Karen L Kotloff, Cynthia L Gay, Joy Nelson, Haoua Dunbar, Joyce S Plested

medRxiv· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical Trial.
Germán Áñez, Lisa M Dunkle, Cynthia L Gay, Karen L Kotloff, Jeffrey M Adelglass, Joyce S Plested

JAMA Netw Open· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Severe Acute Respiratory Syndrome Coronavirus 2 Receptor (Human Angiotensin-Converting Enzyme 2) Binding Inhibition Assay: A Rapid, High-Throughput Assay Useful for Vaccine Immunogenicity Evaluation.
Joyce S Plested, Mingzhu Zhu, Shane Cloney-Clark, Edmond Massuda, Urvashi Patel

Microorganisms· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis